Brad Spellberg

33.0k total citations · 10 hit papers
216 papers, 21.6k citations indexed

About

Brad Spellberg is a scholar working on Infectious Diseases, Epidemiology and Molecular Medicine. According to data from OpenAlex, Brad Spellberg has authored 216 papers receiving a total of 21.6k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Infectious Diseases, 88 papers in Epidemiology and 54 papers in Molecular Medicine. Recurrent topics in Brad Spellberg's work include Antifungal resistance and susceptibility (60 papers), Antibiotic Resistance in Bacteria (54 papers) and Fungal Infections and Studies (44 papers). Brad Spellberg is often cited by papers focused on Antifungal resistance and susceptibility (60 papers), Antibiotic Resistance in Bacteria (54 papers) and Fungal Infections and Studies (44 papers). Brad Spellberg collaborates with scholars based in United States, Canada and Greece. Brad Spellberg's co-authors include John E. Edwards, Ashraf S. Ibrahim, David N. Gilbert, John S. Bradley, Helen W. Boucher, George H. Talbot, John Bartlett, John G. Bartlett, Michael Scheld and Louis B. Rice and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Investigation.

In The Last Decade

Brad Spellberg

208 papers receiving 20.9k citations

Hit Papers

Bad Bugs, No Drugs: No ES... 2001 2026 2009 2017 2008 2007 2005 2017 2005 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
    2008 3.9k citations John E. Edwards, Brad Spellberg et al. Clinical Infectious Diseases profile →
  2. The Epidemic of Antibiotic-Resistant Infections: A Call to Action for the Medical Community from the Infectious Diseases Society of America
    2007 1.3k citations Brad Spellberg, John E. Edwards et al. Clinical Infectious Diseases profile →
  3. Novel Perspectives on Mucormycosis: Pathophysiology, Presentation, and Management
    2005 991 citations Brad Spellberg, John E. Edwards et al. profile →
  4. Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges
    2017 828 citations Darren Wong, Travis B. Nielsen et al. profile →
  5. Necrotizing Fasciitis Caused by Community-Associated Methicillin-ResistantStaphylococcus aureusin Los Angeles
    2005 760 citations Arnold S. Bayer, Brad Spellberg et al. profile →
  6. Type 1/Type 2 Immunity in Infectious Diseases
    2001 673 citations Brad Spellberg, John E. Edwards Clinical Infectious Diseases profile →
  7. Trends in Antimicrobial Drug Development: Implications for the Future
    2004 633 citations Brad Spellberg, Eric P. Brass et al. Clinical Infectious Diseases profile →
  8. Nosocomial fungal infections: epidemiology, diagnosis, and treatment
    2007 565 citations Brad Spellberg et al. profile →
  9. Pathogenesis of Mucormycosis
    2012 508 citations Ashraf S. Ibrahim, Brad Spellberg et al. Clinical Infectious Diseases profile →
  10. The Future of Antibiotics and Resistance
    2013 463 citations Brad Spellberg et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Brad Spellberg 9.6k 7.1k 5.3k 4.5k 2.6k 216 21.6k
Wen‐Chien Ko 7.7k 0.8× 6.1k 0.9× 6.6k 1.2× 2.6k 0.6× 2.3k 0.9× 589 23.1k
Marc J. M. Bonten 8.7k 0.9× 8.6k 1.2× 4.8k 0.9× 4.1k 0.9× 1.1k 0.4× 558 24.7k
John E. Edwards 16.5k 1.7× 12.6k 1.8× 3.4k 0.6× 4.5k 1.0× 2.8k 1.1× 229 27.0k
Shan‐Chwen Chang 7.9k 0.8× 6.6k 0.9× 4.2k 0.8× 2.9k 0.6× 1.3k 0.5× 652 19.0k
Eleftherios Mylonakis 9.3k 1.0× 7.7k 1.1× 1.8k 0.3× 5.4k 1.2× 1.3k 0.5× 430 22.5k
Jean‐Marc Rolain 7.7k 0.8× 3.4k 0.5× 7.6k 1.4× 5.3k 1.2× 1.8k 0.7× 539 23.8k
Arjun Srinivasan 5.2k 0.5× 6.1k 0.9× 9.2k 1.7× 3.4k 0.8× 2.7k 1.0× 215 22.5k
Fernando Baquero 5.9k 0.6× 5.6k 0.8× 12.5k 2.3× 7.8k 1.7× 3.6k 1.4× 493 29.4k
J. Verhoef 5.9k 0.6× 5.7k 0.8× 5.0k 0.9× 5.2k 1.2× 1.7k 0.7× 508 22.2k
William R. Jarvis 12.9k 1.3× 10.7k 1.5× 2.5k 0.5× 3.7k 0.8× 1.5k 0.6× 482 41.9k

Countries citing papers authored by Brad Spellberg

Since Specialization
Citations

This map shows the geographic impact of Brad Spellberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brad Spellberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brad Spellberg more than expected).

Fields of papers citing papers by Brad Spellberg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brad Spellberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brad Spellberg. The network helps show where Brad Spellberg may publish in the future.

Co-authorship network of co-authors of Brad Spellberg

This figure shows the co-authorship network connecting the top 25 collaborators of Brad Spellberg. A scholar is included among the top collaborators of Brad Spellberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brad Spellberg. Brad Spellberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jiao, Yuanyuan, Jun Yan, Dhruvitkumar S. Sutaria, et al.. (2024). Population pharmacokinetics and humanized dosage regimens matching the peak, area, trough, and range of amikacin plasma concentrations in immune-competent murine bloodstream and lung infection models. Antimicrobial Agents and Chemotherapy. 68(3). e0139423–e0139423.
2.
Jiao, Yuanyuan, Jun Yan, Michael Vicchiarelli, et al.. (2023). Individual Components of Polymyxin B Modeled via Population Pharmacokinetics to Design Humanized Dosage Regimens for a Bloodstream and Lung Infection Model in Immune-Competent Mice. Antimicrobial Agents and Chemotherapy. 67(5). e0019723–e0019723. 5 indexed citations
3.
Nielsen, Travis B., Jun Yan, Rachel Li, et al.. (2023). Development of a Bispecific Antibody Targeting Clinical Isolates of Acinetobacter baumannii. The Journal of Infectious Diseases. 227(9). 1042–1049. 12 indexed citations
4.
Yan, Jun, Travis B. Nielsen, Boris Novakovic, et al.. (2023). A protein-free vaccine stimulates innate immunity and protects against nosocomial pathogens. Science Translational Medicine. 15(716). eadf9556–eadf9556. 22 indexed citations
5.
Nielsen, Travis B., Jun Yan, Ulrike MacDonald, et al.. (2021). Capsule carbohydrate structure determines virulence in Acinetobacter baumannii. PLoS Pathogens. 17(2). e1009291–e1009291. 72 indexed citations
6.
Nielsen, Travis B., Jun Yan, Rachel Li, et al.. (2021). Monoclonal Antibody Therapy against Acinetobacter baumannii. Infection and Immunity. 89(10). e0016221–e0016221. 28 indexed citations
7.
Hinchliffe, Philip, Diego M. Moreno, María F. Mojica, et al.. (2021). 2-Mercaptomethyl Thiazolidines (MMTZs) Inhibit All Metallo-β-Lactamase Classes by Maintaining a Conserved Binding Mode. ACS Infectious Diseases. 7(9). 2697–2706. 15 indexed citations
8.
Minejima, Emi, Melissa Mert, Wendy J. Mack, et al.. (2019). Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes. Clinical Infectious Diseases. 70(4). 566–573. 97 indexed citations
9.
Wong, Darren, Paul Holtom, & Brad Spellberg. (2018). Osteomyelitis Complicating Sacral Pressure Ulcers: Whether or Not to Treat With Antibiotic Therapy. Clinical Infectious Diseases. 68(2). 338–342. 46 indexed citations
10.
Thompson, George R., Janis E. Blair, Michael Bolaris, et al.. (2017). Adjunctive Corticosteroid Therapy in the Treatment of Coccidioidal Meningitis. Clinical Infectious Diseases. 65(2). 338–341. 15 indexed citations
11.
Nielsen, Travis B., Paul Pantapalangkoor, Jun Yan, et al.. (2017). Diabetes Exacerbates Infection via Hyperinflammation by Signaling through TLR4 and RAGE. mBio. 8(4). 48 indexed citations
12.
Spellberg, Brad, Ashraf S. Ibrahim, Peter Chin‐Hong, et al.. (2011). The Deferasirox–AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. Journal of Antimicrobial Chemotherapy. 67(3). 715–722. 219 indexed citations
13.
Spellberg, Brad, David R. Andes, Anne M. Anglim, et al.. (2009). Safety and Outcomes of Open-Label Deferasirox Iron Chelation Therapy for Mucormycosis. Antimicrobial Agents and Chemotherapy. 53(7). 3122–3125. 72 indexed citations
14.
Spellberg, Brad, Ashraf S. Ibrahim, Michael R. Yeaman, et al.. (2008). The Antifungal Vaccine Derived from the Recombinant N Terminus of Als3p Protects Mice against the Bacterium Staphylococcus aureus. Infection and Immunity. 76(10). 4574–4580. 123 indexed citations
15.
Ibrahim, Ashraf S., Teclegiorgis Gebremariam, Julie Schwartz, John E. Edwards, & Brad Spellberg. (2008). Posaconazole Mono- or Combination Therapy for Treatment of Murine Zygomycosis. Antimicrobial Agents and Chemotherapy. 53(2). 772–775. 83 indexed citations
16.
Spellberg, Brad. (2008). Phagocytes are Crucial End-Effectors of rAls3p-n Vaccine-Induced Protection Against Murine Disseminated Candidiasis. 46th Annual Meeting. 1 indexed citations
17.
Spellberg, Brad. (2008). Safety and Outcomes of Deferasirox Iron Chelation Therapy for Mucormycosis. 46th Annual Meeting. 3 indexed citations
18.
Ibrahim, Ashraf S., Brad Spellberg, Valentina Avanesian, Yue Fu, & John E. Edwards. (2006). The Anti- Candida Vaccine Based on the Recombinant N-Terminal Domain of Als1p Is Broadly Active against Disseminated Candidiasis. Infection and Immunity. 74(5). 3039–3041. 58 indexed citations
19.
Spellberg, Brad, et al.. (2004). Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. Journal of Antimicrobial Chemotherapy. 54(4). 832–835. 69 indexed citations
20.
Libraty, Daniel H., Koichi Uyemura, D. Jullien, et al.. (1997). Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy.. Journal of Clinical Investigation. 99(2). 336–341. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wen‐Chien Ko Breakdown of academic impact, for papers by Marc J. M. Bonten Breakdown of academic impact, for papers by John E. Edwards Breakdown of academic impact, for papers by Shan‐Chwen Chang Breakdown of academic impact, for papers by Eleftherios Mylonakis Breakdown of academic impact, for papers by Jean‐Marc Rolain Breakdown of academic impact, for papers by Arjun Srinivasan Breakdown of academic impact, for papers by Fernando Baquero Breakdown of academic impact, for papers by J. Verhoef Breakdown of academic impact, for papers by William R. Jarvis
Rankless by CCL
2026